Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis -November 27, 2023 at 09:08 am EST
Acadia Pharmaceuticals Inc. today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with...
United States Alzheimers Dement Acadia Pharmaceuticals Research Definition Acadia Pharmaceuticals Inc Alzheimer Association
Source: marketscreener.com